5-Amino-1MQ

5-Amino-1MQ (also known as 5-amino-1-methylquinolinium, 5A1MQ) is a prominently researched experimental compound classified strictly within the NNMT Inhibitor framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that consumes SAM and depletes NAD+ pools while promoting fat storage. By blocking NNMT, 5-Amino-1MQ raises intracellular NAD+ levels, activates SIRT1, and shifts adipocytes toward lipolysis. Shown in rodent models to reduce fat mass without caloric restriction. with a documented biological half-life of roughly 2 hours, In preclinical investigative trials and independent academic studies, researchers utilizing 5-Amino-1MQ have documented significant, quantifiable biological outcomes, primarily focusing on fat loss, nad+ preservation, metabolic optimization, muscle protection. Typical research protocols investigate administering 50000 to 100000mcg via oral pathways daily. However, it is critically important to understand that while 5-Amino-1MQ demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.